OraSure Technologies (NASDAQ: OSUR - Get Free Report) and Agape ATP (NASDAQ: ATPC - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability. Analyst Recommendations This is a breakdown of
BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick™ HIV Self-Test has received a license from Health Canada for use in Canada.
BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026.
BETHLEHEM, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has nominated two candidates, including the fund's founder Rishi Bajaj, to stand for election to the Company's Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.
LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has nominated two highly-qualified candidates, John Bertrand, Co-Founder of Digital Diagnostics, and Rishi Bajaj, President and CIO of Altai, for election to the OraSure Board of Directors (the “Board”) at the 2026 Annua.
OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.
BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has notified the Company of its intent to nominate two candidates, including the fund's founder, Rishi Bajaj, to stand for election to the Company's Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.
LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. (“Altai”), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter notifying the OraSure Board of Directors (the “Board”) of Altai's intention to nominate two highly-qualified candidates, John Bertrand, CEO of Digital Diagnostics, and Rishi Bajaj, President and CI.
OraSure Technologies, Inc. ( OSUR ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Jason Plagman - Vice President of Investor Relations Carrie Eglinton Manner - President, CEO & Director Kenneth McGrath - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the OraSure Technologies, Inc. 2025 Third Quarter Earnings Conference Call.
OraSure Technologies (OSUR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.01 per share a year ago.
